1. Introduction {#sec1}
===============

Liver cancer has recently been reported to have the sixth highest incidence and to be the fourth leading cause of cancer death among all neoplasms worldwide \[[@B1]\]. Hepatocellular carcinoma (HCC) is the most prevalent type of liver cancer, comprising 75% to 85% of all cases \[[@B2]\]. Hepatectomy remains one of the most effective treatment strategies for selected patients with HCC \[[@B1], [@B3]\]. However, poor prognosis is the biggest obstacle to the treatment of HCCs \[[@B4]\]. Microvascular invasion (MVI) is the risk factor that is most closely related to the prognosis of patients with HCC \[[@B5], [@B6]\] and has therefore been widely studied in recent years \[[@B7]--[@B10]\].

Tumor-related problems in older individuals have recently aroused great concern \[[@B11]\], health problems in this age group being increasingly prominent with the aging of populations worldwide. Over the past two decades, the age-adjusted morbidity of HCC has increased because of aging and population growth \[[@B2], [@B12]\]. It has been reported that age is not associated with prognosis in patients with HCC who have undergone hepatectomy \[[@B13]\]. However, another study found that the survival of older individuals after liver resection for HCC is poor, despite the fact that the estimated relative survival suggests that hepatectomy can benefit these patients \[[@B14]\]. Moreover, older and younger patients with HCC are often treated differently \[[@B15]\].

In terms of the established correlation between MVI and prognosis of HCC and the possible difference in prognosis between younger and older patients, few studies have compared the outcomes of patients with MVI according to age group. Therefore, the aim of this study was to investigate the differences in prognosis between younger and older patients with HCC and MVI (HCC-MVI).

2. Materials and Methods {#sec2}
========================

2.1. Patients {#sec2.1}
-------------

Data of 714 patients with HCC-MVI who had undergone hepatectomy in our department from January 2008 to November 2016 were retrospectively collected. All enrolled patients had pathologically confirmed HCC-MVI. The definition of MVI was microscopic tumor invasion identified in the portal or hepatic vein of the surrounding liver tissue, contiguous with the tumor. In accordance with the definition of the World Health Organization, older patients were defined as those aged 60 years or older \[[@B16]\]. Thus, the patients were allocated to older (age greater than or equal to 60 years) and younger age groups (age less than 60 years) in this study. Our study was approved by the West China Hospital of Sichuan University Biomedical Research Ethics Committee. Because this was a retrospective study of anonymized data, consent to participate was not required. The clinical trial registration number is [ChiCTR2000029320](http://www.chictr.org.cn/showproj.aspx?proj=47271).

To avoid bias, 1 : 1 propensity score matching (PSM) between the two cohorts was performed, and 84 patients enrolled into each group. Inclusion criteria comprised of (1) generally good condition without major organ dysfunction, (2) no history of another malignant tumor, (3) pathologically confirmed MVI, and (4) having undergone curative resection.

2.2. Design {#sec2.2}
-----------

Patients diagnosed with HCC in accordance with published diagnostic criteria for HCC \[[@B17]\] were allocated to older and younger age groups. To fully assess the patient\'s general condition before surgery, abdominal enhanced computed tomography (CT) or magnetic resonance imaging, cardiopulmonary function, and serological testing, including hepatitis B surface antigen, alpha-fetoprotein (AFP), gamma-glutamyl transpeptidase (GGT), aspartate aminotransferase, alanine aminotransferase, white blood cell count, lymphocyte count, and total bilirubin were performed. Disease-free survival (DFS) and overall survival (OS) were compared between the two age groups using the Kaplan--Meier method, and significant differences were identified using log-rank analysis. Univariate and multivariate Cox proportional hazards regression analyses were performed to identify significant and independent risk factors for poor prognosis.

2.3. Follow-Up {#sec2.3}
--------------

Follow-up ended in November 2016 or at death. DFS was defined as time from hepatectomy to the first detectable recurrence and OS time as time from hepatectomy to death or last follow-up. After the operation, the patient was followed up for the first month and thereafter every three months. Routine blood examination, liver function, serum AFP concentrations, and ultrasonic examinations (ultrasound, contrast-enhanced ultrasound) were routinely performed at each follow-up. If a definite or possible recurrence was detected, further tests, such as abdominal enhanced CT or abdominal enhanced magnetic resonance imaging, were performed and treatment decisions made after the patient\'s condition had been fully assessed by our multidisciplinary team, which consisted of hepatic surgeons, an oncologist, and a radiologist.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Categorical variables were compared using the *χ*^2^ or Fisher exact test, whereas continuous variables were compared using the Mann--Whitney *U* test. Survival curves of the two study groups were constructed using the Kaplan--Meier method, and the survival curves were compared using the log-rank test. To identify factors independently associated with OS and DFS, univariate analysis was carried out using a Cox proportional hazards stepwise model; the significant (*P* \< 0.05) variables were then subjected to stepwise multivariate analysis. To overcome possible selection bias, 1 : 1 PSM between the old group and young group was applied using the nearest-neighbour matching method with a caliper of 0.02 \[[@B18]\]. All analyses were performed using SPSS Statistics version 22.0 for Windows (IBM Corp).

3. Results and Discussion {#sec3}
=========================

3.1. Patient Characteristics {#sec3.1}
----------------------------

A total of 714 eligible patients were retrospectively identified. The final analysis did not include individuals who were excluded because they were found to have other malignancies during follow-up (*n* = 2), had data missing (*n* = 105), were pathologically confirmed as having mixed-type HCC (*n* = 2), had recurrence within 4 weeks (*n* = 3), or were lost to follow-up (*n* = 228). Finally, 374 patients were included in the analysis ([Figure 1](#fig1){ref-type="fig"}). As shown in [Table 1](#tab1){ref-type="table"}, the baseline characteristics of the two age groups differed before the PSM, whereas after the PSM, there were no significant differences between them ([Table 2](#tab2){ref-type="table"}). No significant differences in intraoperative or postoperative characteristics were identified between the two age groups ([Table 3](#tab3){ref-type="table"}).

3.2. Survival Analysis {#sec3.2}
----------------------

Before PSM analysis, the estimated 6-month, 1-year, 2-year, and 5-year recurrence rates in the younger group were 62.8%, 76.4%, 83.7%, and 90.3%, respectively, and in the older group were 43.5%, 56.5%, 68.5%, and 82.2%, respectively ([Figure 2(a)](#fig2){ref-type="fig"}; *P* \< 0.001). The estimated 6-month, 1-year, 2-year, and 5-year OS rates were 75.5%, 54.2%, 33.9%, and 22.2%, respectively, in the younger group and 82.6%, 73.9%, 54.3%, and 37.3%, respectively, in the older group ([Figure 2(b)](#fig2){ref-type="fig"}; *P* = 0.001). After PSM, the estimated 6-month, 1-year, 2-year, and 5-year recurrence rates were 63.1%, 76.2%, 84.5%, and 90.0%, respectively, in the younger group and, the 42.9%, 56.0%, 69.0%, and 82.1%, respectively, in the older group ([Figure 2(c)](#fig2){ref-type="fig"}; *P* = 0.006). The estimated 6-month, 1-year, 2-year, and 5-year OS rates were 81.0%, 58.3%, 34.5%, and 23.2%, respectively, in the younger group and 84.5%, 75.0%, 54.8%, and 38.9%, respectively, in the older group ([Figure 2(d)](#fig2){ref-type="fig"}; *P* = 0.010).

3.3. Independent Risk Factors of Prognosis {#sec3.3}
------------------------------------------

As shown in [Table 4](#tab4){ref-type="table"}, on univariate analysis, age, postoperative adjuvant transcatheter arterial chemoembolization (TACE), Barcelona Clinic Liver Cancer (BCLC) stage, and lymphocyte (LYM) count were identified as significant risk factors for DFS, and age, BCLC stage, reoperation, giant vascular invasion, and LYM count were identified as significant risk factors for OS. Multivariate analyses revealed that the following factors were significantly associated with DFS: age (hazard ratio, 1.590; 95% CI, 1.135--2.228), postoperative adjuvant TACE (hazard ratio, 1.647; 95% CI, 1.170--2.320), and LYM count (hazard ratio, 0.653; 95% CI, 0.484--0.880). Similarly, multivariate analyses showed that age (hazard ratio, 1.837; 95% CI, 1.259--2.680), reoperation (hazard ratio, 1.647; 95% CI, 1.170--2.320), and LYM count (hazard ratio, 0.592; 95% CI, 0.419--0.838) were associated with OS.

4. Discussion {#sec4}
=============

Our study was large, enabling us to perform PSM. There were no statistically significant differences in baseline data between the age groups selected by PSM. We mainly investigated the difference in prognosis between older and younger patients with MVI. Unlike other studies that have reported that age is not a risk factor for prognosis or that older adults have a worse prognosis than younger ones \[[@B19], [@B20]\], we found that older patients have a better prognosis than younger ones.

The biological behaviour of HCC reportedly differs greatly between younger and older individuals. The reasons for this difference are not fully understood but are likely due to differences in hepatocarcinogenesis \[[@B21], [@B22]\]. Previous data have indicated that androgen receptor (AR) and phosphoinositide-3 kinase (PI3K) are upregulated and become dominant pathways in tumor tissues with aging \[[@B23]--[@B25]\]. Overexpression of AR and PI3K pathways is significantly associated with poor survival \[[@B25]--[@B28]\]. This is at variance with the finding in our study that older age is associated with a better survival in patients with HCC.

This discrepancy may be attributable to the fact that our study included only patients with MVI. Some previous studies have reported that younger patients have a worse prognosis, which is consistent with our results; however, those researchers considered that the poorer prognosis is mainly attributable to worse tumor-related indicators, such as larger tumor diameter, later tumor stage, and higher AFP concentration \[[@B15] , [@B29], [@B30]\]. In our study, both before and after performing PSM, there was no significant difference in these indicators between the two age groups of patients. We therefore do not believe that the identified prognostic differences are solely due to differences in these factors. MVI status was not considered in the abovementioned studies, despite it reportedly being strongly associated with a poor prognosis \[[@B5], [@B6]\]. As mentioned earlier, differences in age can be associated with different biological behaviours and some researchers consider that the impact of MVI status on the biological behaviour of tumors varies with age \[[@B31], [@B32]\]. Thus, differences in age may lead to different biological behaviours of MVI, resulting in different outcomes.

One of the drivers of the increasing incidence of HCC is the progressive aging of the population, which reportedly contributed 16% of the 38% increase in cases from 2006 to 2016 \[[@B33]\]. Some studies have found that older patients are less tolerant than younger patients to surgical resection, which is a complex procedure, and thus may be treated more conservatively than younger patients for the same condition \[[@B15], [@B34]\]. However, a growing body of research has confirmed that older patients with HCC who undergo resection can achieve outcomes comparable to those of younger patients \[[@B13], [@B14], [@B23], [@B35]\]. This is largely attributable to considerable improvements in postoperative medical care and therefore better control of postoperative complications in older patients. Even individuals older than 75 years have been reported to undergo surgery safely \[[@B36]\]. In addition, in our study data, we found no significant differences in intraoperative or postoperative clinical variables between the two age groups of patients. Therefore, postoperative complications are no longer a barrier to surgery on older patients. Admittedly, the cardiopulmonary function of the older patients in our study was rigorously assessed.

The BCLC classification system for HCCs does not include age or MVI \[[@B2]\]; we believe that more attention to these two factors is justified. Older people tend to receive more conservative treatment than younger individuals for the same condition and thus may miss out on the most effective treatments. The present study provides evidence for treating older persons more actively. In addition, with their poor prognosis, more aggressive preventive measures should be recommended to younger individuals who undergo hepatectomy and have histopathologically confirmed MVI to reduce the likelihood of recurrence.

This study had some limitations. First, it was a retrospective study, albeit including PSM. Randomized controlled trials are needed to confirm our findings. Second, the sample size was relatively small after PSM. Thus, our findings should be verified in larger studies. Future studies should also investigate the correlation of other risk factors, especially those that are well recognized, and age in the prognoses of patients with HCC-MVI.

5. Conclusions {#sec5}
==============

In patients with histologically confirmed HCC-MVI, the prognosis of those older than 60 years is superior to that of younger patients. Older individuals can undergo hepatectomy safely, and postoperative complications are no longer a barrier to surgery for them.
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![Flow chart of the study participants.](GRP2020-4691425.001){#fig1}

![Kaplan--Meier analysis of disease-free survival and overall survival for hepatocellular carcinoma patients with microvascular invasion: (a) disease-free survival for the young group and old group before PSM. (b) Overall survival for the young group and old group before PSM. (c) Disease-free survival for the young group and old group after PSM. (d) Overall survival for the young group and old group after PSM.](GRP2020-4691425.002){#fig2}

###### 

Baseline characteristics of the study participants before PSM.

  Variable                    Young group            Old group             *P* value
  --------------------------- ---------------------- --------------------- -----------
  Gender (male)               250 (88.7%)            78 (84.8%)            0.326
  Adjuvant TACE               126 (44.7%)            32 (34.8%)            0.095
  Reoperation                 29 (10.3%)             5 (5.4%)              0.160
  Tumor diameter (cm)         8.1 ± 3.8              7.5 ± 3.4             0.154
  Tumor number (single)       209 (74.1%)            67 (72.8%)            0.807
  GVI                         97 (34.4%)             27 (29.3%)            0.372
  Transfusion                 43 (15.2%)             12 (13.0%)            0.604
  Diabetes                    11 (3.9%)              10 (10.9%)            0.012
  HBsAg positivity            261 (92.6%)            71 (77.2%)            \<0.001
  AFP (ng/mL) (IQR)           1210.0 (45.8-1210.0)   324.1 (17.2-1210.0)   0.046
  Invading adjacent organs    33 (11.7%)             11 (12.0%)            0.948
  Anatomic resection          175 (62.1%)            55 (59.8%)            0.697
  Well differentiation        121 (42.9%)            48 (52.2%)            0.121
  Invasion of liver capsule   81 (28.7%)             28 (30.4%)            0.754
  Satellite nodules           65 (23.0%)             9 (9.8%)              0.006
  Lymphatic metastasis        11 (3.9%)              3 (3.3%)              0.779
  Cirrhosis                   140 (49.6%)            40 (43.5%)            0.304
  GGT level (U/L) (IQR)       101.0 (50.0-201.0)     77.5 (43.5-119.8)     0.006
  ALT level (U/L) (IQR)       42.0 (30.0-67.0)       36.0 (25.0-59.3)      0.028
  AST level (U/L) (IQR)       50.0 (33.8-78.0)       45.5 (31.0-70.8)      0.217
  TBIL level (mmol/L)         12.4 ± 1.3             12.0 ± 1.1            0.006
  LYM count (10^9^/L) (IQR)   1.4 (1.0-1.8)          1.3 (1.0-1.9)         0.933
  WBC count (10^9^/L) (IQR)   5.5 (4.5-6.8)          5.4 (4.3-6.7)         0.928
  BCLC staging                                                             0.597
   A                          48 (17.0%)             15 (16.3%)            
   B-C                        234 (82.9%)            77 (83.7%)            
  Child-Pugh                                                               0.592
   A                          262 (92.9%)            88 (95.7%)            
   B                          17 (6.0%)              3 (3.3%)              
   C                          3 (1.1%)               1 (1.1%)              

Abbreviations: TACE: transcatheter arterial chemoembolization; GVI: giant vascular invasion; HBsAg: hepatitis B surface antigen; AFP: alpha fetoprotein; IQR: interquartile range; GGT: gamma-glutamyl transpeptidase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; TBIL: total bilirubin; LYM: lymphocyte; WBC: white blood cell; BCLC: Barcelona Clinic Liver Cancer.

###### 

Baseline characteristics of the study participants after PSM.

  Variable                    Young group            Old group             *P* value
  --------------------------- ---------------------- --------------------- -----------
  Gender (male)               71 (84.5%)             70 (83.3%)            0.834
  Adjuvant TACE               37 (44.0%)             29 (34.5%)            0.206
  Reoperation                 10 (11.9%)             5 (6.0%)              0.176
  Tumor diameter (cm)         7.6 ± 3.6              7.3 ± 3.1             0.583
  Tumor number (single)       65 (77.4%)             61 (72.6%)            0.476
  GVI                         24 (28.6%)             25 (29.8%)            0\. 865
  Transfusion                 8 (9.5%)               10 (11.9%)            0.618
  Diabetes                    8 (9.5%)               5 (6.0%)              0.386
  HBsAg positivity            73 (86.9%)             68 (81.0%)            0.294
  AFP (ng/mL) (IQR)           1210.0 (65.4-1210.0)   324.1 (17.2-1210.0)   0.134
  Invading adjacent organs    10 (11.9%)             9 (10.7%)             0.808
  Anatomic resection          48 (57.1%)             50 (59.5%)            0.754
  Well differentiation        33 (39.3%)             42 (50.0%)            0.162
  Invasion of liver capsule   22 (26.2%)             25 (29.8%)            0.606
  Satellite nodules           11 (13.1%)             9 (10.7%)             0.634
  Lymphatic metastasis        4 (4.8%)               3 (3.6%)              0.699
  Cirrhosis                   40 (47.6%)             37 (44.0%)            0.642
  GGT level (U/L) (IQR)       75.5 (43.5-129.5)      67.0 (42.3-119.8)     0.526
  ALT level (U/L) (IQR)       43.0 (28.5-66.8)       37.5 (25.0-60.8)      0.124
  AST level (U/L) (IQR)       45.5 (33.0-69.5)       47.0 (32.3-71.0)      0.858
  TBIL level (mmol/L)         12.0 ± 1.2             12.0 ± 1.1            0.852
  LYM count (10^9^/L)         1.5 ± 0.6              1.5 ± 0.6             0.876
  WBC count (10^9^/L) (IQR)   5.4 (4.4-6.9)          5.4 (4.3-6.7)         0.878
  BCLC stage                                                               0.592
   A                          18 (21.4%)             13 (15.5%)            
   B-C                        64 (78.6%)             71 (84.6%)            
  Child-Pugh                                                               0.592
   A                          79 (94.0%)             81 (96.4%)            
   B                          2 (2.4%)               3 (3.6%)              
   C                          3 (3.6%)               0 (0.0%)              

Abbreviations: TACE: transcatheter arterial chemoembolization; GVI: giant vascular invasion; AFP: alpha fetoprotein; IQR: interquartile range; GGT: gamma-glutamyl transpeptidase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; TBIL: total bilirubin; LYM: lymphocyte; WBC: white blood cell; BCLC: Barcelona Clinic Liver Cancer.

###### 

Intraoperative and postoperative characteristics of the study participants after PSM.

  Variable                                       Young group       Old group         *P* value
  ---------------------------------------------- ----------------- ----------------- -----------
  Intraoperative blood loss (mL) (IQR)           300 (200-437.5)   300 (200-575.5)   0.398
  Intraoperative RBC transfusion (U) (EVR)       0 (0-17.5)        0 (0-7)           0.779
  Intraoperative plasma transfusion (mL) (EVR)   0 (0-1800)        0 (0-400)         0.680
  Postoperative RBC transfusion (U) (EVR)        0 (0-3)           0 (0-2)           0.690
  Postoperative plasma transfusion (mL) (EVR)    0 (0-2100)        0 (0-400)         0.972
  Postoperative hospital stays (day) (IQR)       7 (6-9.75)        8 (7-10)          0.175
  Postoperative complications^1^                                                     0.801
   Grade I                                       5 (6.0%)          3 (3.6%)          
   Grade II                                      8 (9.5%)          12 (14.3%)        
   Grade IIIa                                    2 (2.4%)          1 (1.2%)          
   Grade IIIb                                    0 (0.0%)          0 (0.0%)          
   Grade IVa                                     2 (2.4%)          2 (2.4%)          
   Grade IVb                                     0 (0.0%)          0 (0.0%)          
   Grade V                                       0 (0.0%)          0 (0.0%)          
  Liver failure^2^                                                                   1.000
   Grade A                                       1 (1.2%)          1 (1.2%)          
   Grade B                                       1 (1.2%)          1 (1.2%)          
   Grade C                                       0 (0.0%)          0 (0.0%)          

^1^Postoperative complication is graded according to the Clavien-Dindo classification of surgical complications. ^2^Liver failure is graded according to the International Study Group of Liver Surgery (ISGLS) classification. Abbreviations: IQR: interquartile range; EVR: extreme value range; RBC: red blood cell.

###### 

Uni- and multivariate analyses of disease-free survival (DFS) and overall survival (OS).

  Variable                               Number   Univariate             Multivariate                          
  -------------------------------------- -------- ---------------------- -------------- ---------------------- -------
  DFS                                                                                                          
   Age, \<60/≥60 y                       84/84    1.562 (1.119--2.181)   0.009          1.590 (1.135--2.228)   0.007
   Postoperative adjuvant TACE, no/yes   102/66   1.652 (1.176--2.320)   0.004          1.647 (1.170--2.320)   0.004
   BCLC staging, B-C stage/A stage       137/31   1.293 (1.000--1.671)   0.050          1.288 (0.995--1.667)   0.055
   LYM count, ≤1100/\>1100/*μ*L          50/118   0.672 (0.507--0.890)   0.006          0.653 (0.484--0.880)   0.005
  OS                                                                                                           
   Age, \<60/≥60 y                       84/84    1.608 (1.110--2.328)   0.012          1.837 (1.259--2.680)   0.002
   Reoperation, no/yes                   153/15   2.313 (1.075--4.976)   0.032          1.647 (1.170--2.320)   0.011
   GVI, yes/no                           49/119   1.795 (1.217--2.648)   0.003          1.293 (0.670--2.494)   0.443
   BCLC staging, B-C stage/A stage       137/31   1.543 (1.164--2.045)   0.003          1.349 (0.846--2.151)   0.209
   LYM count, ≤1100/\>1100/*μ*L          50/118   0.645 (0.467--0.891)   0.008          0.592 (0.419--0.838)   0.003

Abbreviations: HR: hazard ratio; CI: confidence interval.
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